Den totala incidensen av biverkningar som rapporterades vid behandling med telmisartan (41, 4%) var vanligen jämförbar med placebo (43, 9%) i placebo- kontrollerade studier. ###>The overall incidence of adverse events reported with telmisartan (41.4%) was usually comparable to placebo (43.9%) in placebo controlled trials.